Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN) and Cardinal Health (CAH)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Qiagen (QGEN – Research Report) and Cardinal Health (CAH – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Qiagen (QGEN)
William Blair analyst Andrew Brackmann maintained a Hold rating on Qiagen today. The company’s shares closed last Wednesday at $51.71.
According to TipRanks.com, Brackmann is a 5-star analyst with an average return of
Currently, the analyst consensus on Qiagen is a Moderate Buy with an average price target of $53.04, representing a 1.6% upside. In a report issued on January 21, Nephron also downgraded the stock to Hold with a $59.00 price target.
See today’s best-performing stocks on TipRanks >>
Cardinal Health (CAH)
In a report released today, Charles Rhyee from TD Cowen maintained a Buy rating on Cardinal Health, with a price target of $233.00. The company’s shares closed last Wednesday at $206.85.
According to TipRanks.com, Rhyee is a 4-star analyst with an average return of
Currently, the analyst consensus on Cardinal Health is a Strong Buy with an average price target of $242.00, which is a 12.3% upside from current levels. In a report issued on January 22, Jefferies also maintained a Buy rating on the stock with a $270.00 price target.
